We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.91B
1-Year Est. Return 304.52%
This Fund
S&P 500
This Quarter Est. Return
+4.78%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.92%
10 Year Est. Return
+28,184.58%
AUM
$2.76B
AUM Growth
+$192M
Cap. Flow
+$562M
Cap. Flow %
20.4%
Top 10 Hldgs %
46.52%
Holding
86
New
11
Increased
24
Reduced
9
Closed
3

Top Buys

Rank Stock Value
1
MRUS
Merus
MRUS
+$117M
2
CGEM icon
Cullinan Oncology
CGEM
+$92.4M
3
EQRX
EQRx, Inc. Common Stock
EQRX
+$74.2M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$51.3M
5
CRNX
Crinetics Pharmaceuticals
CRNX
+$50.5M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$45.6M
2
RVMD icon
Revolution Medicines
RVMD
+$19M
3
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$16.5M
4
ANAB icon
AnaptysBio
ANAB
+$9.07M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$7.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.18%
2 Financials 0.46%
3 Miscellaneous 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIRX
51
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$12.6M 0.46%
3,438,944
+344,770
+11% +$1.84M
MTEM
52
DELISTED
Molecular Templates, Inc.
MTEM
$12.3M 0.45%
208,640
+18,200
+10% +$1.36M
CFRX
53
DELISTED
ContraFect Corporation
CFRX
$10.4M 0.38%
49,654
– –
ELEV
54
DELISTED
Elevation Oncology
ELEV
$9.7M 0.35%
1,611,698
+21,400
+1% +$148K
LITS
55
Lite Strategy Inc
LITS
$34.7M
$9.43M 0.34%
176,603
– –
CDTX
56
DELISTED
Cidara Therapeutics
CDTX
$8.71M 0.32%
343,056
+104,211
+44% +$3.24M
MOLN
57
Molecular Partners
MOLN
$150M
$8.55M 0.31%
443,221
+24,213
+6% +$407K
NUVL
58
DELISTED
Nuvalent
NUVL
$8.54M 0.31%
448,512
– –
IVA
59
Inventiva
IVA
$895M
$7.44M 0.27%
544,500
– –
CNCE
60
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$7.1M 0.26%
+2,253,000
New +$7.5M
MIRM icon
61
Mirum Pharmaceuticals
MIRM
$6.32B
$6.95M 0.25%
435,936
– –
ELDN icon
62
Eledon Pharmaceuticals
ELDN
$217M
$6.08M 0.22%
1,378,020
+14,585
+1% +$73.8K
RNAC icon
63
Cartesian Therapeutics
RNAC
$239M
$5.62M 0.2%
57,438
+46,782
+439% +$5.03M
CNTA
64
DELISTED
Centessa Pharmaceuticals
CNTA
$5.12M 0.19%
+454,545
New +$6.12M
EUCRU
65
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$4.99M 0.18%
500,000
– –
CALA
66
DELISTED
Calithera Biosciences, Inc
CALA
$4.96M 0.18%
372,617
– –
FLACU
67
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$4.95M 0.18%
500,000
– –
FVAM
68
DELISTED
5:01 Acquisition Corp
FVAM
$4.92M 0.18%
500,000
– –
RACB
69
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$4.86M 0.18%
500,000
– –
GNCA
70
DELISTED
Genocea Biosciences, Inc.
GNCA
$4.65M 0.17%
4,012,404
– –
CRVS icon
71
Corvus Pharmaceuticals
CRVS
$1.03B
$3.3M 0.12%
1,370,947
– –
EOCN
72
Eocene Ltd. Ordinary Shares
EOCN
$3.64M
$3.27M 0.12%
1,250
– –
ELTX icon
73
Elicio Therapeutics
ELTX
$46.5M
$3.11M 0.11%
107,130
– –
PHXM
74
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$3.1M 0.11%
131,466
– –
RNTX
75
Rein Therapeutics
RNTX
$60.6M
$2.96M 0.11%
263,278
– –
1 2
3
4

Similar funds

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.91B AUM 14.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
AC
Anther Capital Hong Kong $3.91B AUM
FFGIM
Founders Fund Growth II Management San Francisco, California $3.9B AUM
AIM
ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

BVF Inc's Q4 2021 Portfolio in Review

As of Q4 2021, BVF Inc held 86 positions worth $2.76B, up 7.5% from $2.56B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

BVF Inc deployed $562M of net new capital in Q4 2021, opening 11 new positions and adding to 24 existing holdings. Its largest new stake was Merus: 4,135,071 shares worth $131M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was argenx, an estimated $45.6M trimmed.

  • BVF Inc's largest Q4 2021 buy was Merus: 4,135,071 shares worth $131M.
  • BVF Inc added most to Cullinan Oncology in Q4 2021, an estimated $92.4M increase.
  • BVF Inc's biggest Q4 2021 reduction was argenx, cutting an estimated $45.6M.
  • BVF Inc fully exited Gritstone bio, Inc. Common Stock in Q4 2021, selling an estimated $16.5M.
  • BVF Inc's ten largest holdings make up 47% of its $2.76B portfolio in Q4 2021.
  • BVF Inc opened 11 new positions and closed 3 in Q4 2021.
  • BVF Inc's portfolio value rose 7.5% quarter-over-quarter to $2.76B.

Based on BVF Inc's 13F filing for Q4 2021, filed 14 Feb 2022.